Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal ...

It is the latest in a string of alliances announced by Boehringer in the NASH area in recent years, coming after earlier deals with Dicerna and MiNA Therapeutics – which both involved RNA-based ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with ... stage candidates partnered with Dicerna and UBE. Novo Nordisk follows ...

Background: The rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has led to an increased occurrence of steatotic liver grafts (SLG) in liver transplantation (LT).

M-FY is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol-Myers Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $38.88, with a -1.09% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.16%.

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...